Information  X 
Enter a valid email address
  Print          More announcements

Thursday 30 September, 2021

Morgan Stanley Smith

Form 8.3 - XERIS PHARMACEUTICALS INC

RNS Number : 5490N
Morgan Stanley Smith Barney LLC
30 September 2021
 

 

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BYPERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

 1.  KEY INFORMATION

 

Nameofpersondealing (Note 1)

Morgan Stanley Smith Barney LLC

Companydealtin

XERIS PHARMACEUTICALS  INC

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note2)

$0.001 COMMON STOCK

Date of dealing

29 September 2021

 

2.  INTERESTS AND SHORT POSITIONS

 

  (a)   Interests and short positions (following dealing) in the class of relevant security

  dealt in ( Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

13,206

0.02

  0

    0.00

(2)Derivatives (other than options)

0

0.00

  0

  0.00

(3)Options and agreements to purchase/sell

0

0.00

  0

  0.00

Total

13,206

0.02

  0

  0.00

                 

 

 

(b)  Interests and short positions in relevant securities of the company, other than the  

  class dealt in ( Note 3 )

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

0

0.00

  0

    0.00

(2)Derivatives (other than options)

0

0.00

  0

  0.00

(3)Options and agreements to purchase/sell

0

0.00

  0

  0.00

Total

0

0.00

  0

  0.00

                 

 

 

 

 

 

1.  DEALINGS (Note 4)

(a)  Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

PURCHASE

17

2.4881 USD

SALE

15

2.4800 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g.CFD

Natureoftransaction

(Note6)

Numberofrelevantsecurities

(Note7)

Priceperunit

(Note5)

N/A

N/A

N/A

N/A

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g.calloption

Writing,selling,purchasing,varyingetc.

Numberofsecuritiestowhichtheoptionrelates(Note 7)

Exerciseprice

Type,e.g.American,Europeanetc.

Expirydate

Optionmoneypaid/receivedperunit(Note 5)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

 

(ii)  Exercising

 

Productname,

e.g.calloption

Numberofsecurities

Exercisepriceper unit(Note5)

N/A

N/A

N/A

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Natureoftransaction

(Note8)

Details

Priceperunit

(if applicable) (Note 5)

N/A

N/A

N/A

 

 

 

2.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Fulldetailsofanyagreement,arrangementorunderstandingbetweenthepersondisclosing andanyotherpersonrelatingtothevotingrightsofanyrelevantsecuritiesunderanyoption referredtoonthisformorrelatingtothevotingrightsorfutureacquisitionordisposalofanyrelevantsecuritiestowhichanyderivativereferredtoonthisformisreferenced.Ifnone,this shouldbestated.

 

 

NONE

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)     NO

 

Dateofdisclosure

30 September 2021

Contact name

Craig Horsley

Telephone number

+44 141 245-7736

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

N/A

If aconnectedEFM,statenatureofconnection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEGCGDCGDXDGBG

a d v e r t i s e m e n t